DE602006011859D1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
DE602006011859D1
DE602006011859D1 DE602006011859T DE602006011859T DE602006011859D1 DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1 DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1
Authority
DE
Germany
Prior art keywords
individuals
laten
barr
epstein
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011859T
Other languages
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Lille 2 Droit et Sante
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Universite Lille 2 Droit et Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Universite Lille 2 Droit et Sante filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602006011859D1 publication Critical patent/DE602006011859D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006011859T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon Active DE602006011859D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
DE602006011859D1 true DE602006011859D1 (de) 2010-03-11

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011859T Active DE602006011859D1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (de)
EP (1) EP1861418B1 (de)
JP (1) JP4972562B2 (de)
AT (1) ATE455791T1 (de)
CA (1) CA2596929C (de)
DE (1) DE602006011859D1 (de)
FR (1) FR2881746B1 (de)
WO (1) WO2006082313A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3971454B2 (ja) * 1993-10-29 2007-09-05 ザ トラスティーズ オブ ボストン ユニバーシティ 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
JP6659535B2 (ja) 2013-06-28 2020-03-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
CN104491857B (zh) * 2014-12-24 2018-08-31 深圳市中美康士生物科技有限公司 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法
KR20180128915A (ko) 2016-02-26 2018-12-04 오클랜드 유니서비시즈 리미티드 아미노산 및 펩티드 접합체 및 접합 방법
SI3580561T1 (sl) 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
EA202091178A1 (ru) * 2017-12-20 2020-09-01 Глаксосмитклайн Байолоджикалс Са Антигенные конструкции на основе вируса эпштейна-барр
CN113474840A (zh) * 2018-12-21 2021-10-01 百欧恩泰美国公司 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统
EP3976198A4 (de) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. Verfahren zur behandlung von viral assoziiertem krebs mit histon-deacetylase-inhibitoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
EP1233781A1 (de) * 1999-11-24 2002-08-28 Oklahoma Medical Research Foundation Testverfahren und therapien für latenter viraler infektion
EP1229043A1 (de) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptiden abgeleitet VON Epstein Barr virus (EBV) Proteine LMP1, LMP2 und BARF1
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
AU2003246485A1 (en) * 2002-07-16 2004-02-02 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
TW200416043A (en) * 2002-11-07 2004-09-01 Queensland Inst Med Res Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
WO2006082313A2 (fr) 2006-08-10
ATE455791T1 (de) 2010-02-15
FR2881746B1 (fr) 2007-04-13
WO2006082313A3 (fr) 2007-01-11
US20090130134A1 (en) 2009-05-21
EP1861418A2 (de) 2007-12-05
CA2596929C (fr) 2015-12-29
EP1861418B1 (de) 2010-01-20
JP2008529486A (ja) 2008-08-07
FR2881746A1 (fr) 2006-08-11
CA2596929A1 (fr) 2006-08-10
JP4972562B2 (ja) 2012-07-11

Similar Documents

Publication Publication Date Title
DE602006011859D1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200701918A1 (ru) Белок липокалин
TW200728466A (en) Antibody molecules having specificity for human IL-6
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
IL182403A0 (en) Systems and methods for ex-vivo organ care
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
DK1694706T3 (da) Modificeret anti-CD52-antistof
EP1557462A3 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
DK1713438T3 (da) Medicinsk sæbe
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
WO2007026078A3 (fr) Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
EP2277918A3 (de) Vom Tumorantigen 5t4 abgeleitete Mhc-Klasse-I- und II-Peptidantigene
WO2010080188A3 (en) Epitope targeted anthrax vaccine
ATE474582T1 (de) Pharmazeutische zusammensetzung enthaltend glucan aus mikroalgen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITE DE LILLE II, LILLE, FR

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, , FR